Drug Trial Radar · NCT00089505
NNRTI vs PI Regimens for HIV Infected Women After They Have Taken Nevirapine to Prevent Mother-To-Child HIV Transmission
Last checked: Nov 19, 2026Latest source record: Oct 12, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
745
Actual
Start
Nov 2006
Primary completion
Aug 2010
Study completion Feb 2011
Sponsor
- Lead sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other InfectionsResearch network
- Sponsor type
- Research network
- Collaborators
- National Institute of Allergy and Infectious Diseases (NIAID)
- First posted
- Aug 6, 2004
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 13 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are commonly included in anti-HIV drug regimens. However, HIV infected women who have previously taken the single dose NNRTI nevirapine (SD NVP) for the prevention of mother-to-child transmission (MTCT) of HIV may not respond as well to NNRTIs as women who have never taken NVP. Another class of anti-HIV drugs, protease inhibitors (PIs), may be more effective for women who have previously taken NNRTIs. This study will compare the effectiveness of NNRTI- and PI-based regimens in women who have taken NVP for prevention of MTCT of HIV. This study will also compare regimens including an NNRTI with regimens including a PI in women who have never taken NVP.
Conditions
- HIV Infections
Interventions
EmtricitabineDrug
200 mg taken orally
Emtricitabine/Tenofovir disoproxil fumarateDrug
200/300 mg taken orally
Lopinavir/RitonavirDrug
400/100 mg taken orally
NevirapineDrug
200 mg taken orally
Tenofovir disoproxil fumarateDrug
300 mg taken orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time From Randomization to Virologic Failure or Death for Participants Who Had SD NVP Exposure Prior to Study EntryTime frame: Through database cutoff for DSMB review (by October 6, 2008) with median follow-up 72 weeks and range from 0 to 144 weeks.
- Time From Randomization to Virologic Failure or Death for Participants Without SD NVP Exposure Prior to Study EntryTime frame: Throughout study with median follow-up 72 weeks and range from 0 to 180 weeks.
Locations
11 sites in 7 countries. Site status is shown where the registry gives one.
Molepolole BHP Study Clinic, Scottish Livingstone Hospital
Bontleng Gaborone, Botswana
The Gaborone BHP Study Clinic
Bontleng, Gaborone, Botswana
Moi University International Clnical Trials Unit
Eldoret, Kenya
KMRI / Walter Reed Project Clinical Research Center
Kericho, Kenya
University of North Carolina Project (UNC Project)
Lilongwe, Malawi
Chris Hani Baragwanath Hospital, Johannesburg
Johannesburg, South Africa
University of Witwatersrand
Johannesburg, South Africa
University of KwaZulu Natal
Durban, KwaZulu-Natal, South Africa
Joint Clinical Research Centre (JCRC)
Kampala, Uganda
Centre for Infectious Disease Research in Zambia (CIDRZ)
Lusaka, Zambia
University of Zimbabwe
Avondale, Harare, Zimbabwe
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.